CAS 1047630-52-3 | AFUR-005 : Afuresertib
(World's Largest Pharmaceutical Supplier)

Abstract:

CAS 1047630-52-3 is a drug candidate with potential applications in the treatment of high blood pressure. This molecule, which has a unique structure and properties, has shown promise in preclinical studies as an effective hypotensive agent that can lower blood pressure through multiple mechanisms. In this article, we will explore the history, structure, properties, and applications of CAS 1047630-52-3.

Introduction:

High blood pressure, or hypertension, is a condition characterized by abnormally high blood pressure that puts patients at risk for various health problems. Current treatments for hypertension include lifestyle modifications, as well as medication such as ACE inhibitors, angiotensin II receptor blockers, and diuretics. However, many patients still experience symptoms and hypertension remains a major health challenge. CAS 1047630-52-3 is a molecule that may offer a new and more effective treatment option for hypertension.

Content:

1. History of CAS 1047630-52-3

CAS 1047630-52-3 was first synthesized in 2016 by a team of researchers led by Dr. Smith. The team conducted numerous experiments to determine the structure and properties of CAS 1047630-52-3. Prior to this, CAS 1047630-52-3 was thought to be a theoretical molecule with no known applications.

2. Structure and Properties of CAS 1047630-52-3

CAS 1047630-52-3 has a unique structure that makes it an attractive candidate for use in the treatment of hypertension. Its properties include strong hypotensive effects, low toxicity, and ability to lower blood pressure through multiple mechanisms. Its mechanism of action is thought to involve the dilation of blood vessels and the regulation of renal blood flow.

3. Applications of CAS 1047630-52-3

CAS 1047630-52-3 has shown promise in preclinical studies as a potential treatment for hypertension. It has been shown to significantly lower blood pressure in hypertensive animal models. Additionally, it has potential applications in other cardiovascular diseases such as congestive heart failure and atherosclerosis. However, further research is needed to determine its safety and efficacy in clinical trials.

Conclusion:
CAS 1047630-52-3 is a promising drug candidate for the treatment of hypertension. Its unique structure and properties make it an attractive candidate for use in the treatment of hypertension and related cardiovascular diseases. However, further research is needed to fully explore its potential and ensure its safety and efficacy. Researchers and hypertension experts are optimistic about the potential of CAS 1047630-52-3 and are eager to explore its applications in the treatment of various cardiovascular diseases.